Mitomycin is an antitumor antibiotic that was first isolated in the 1950s from Streptomyces caespitosus and later developed as a chemotherapeutic agent. It was introduced into clinical practice in the 1960s due to its potent ability to inhibit DNA synthesis in rapidly dividing cells. Unlike antiretroviral drugs such as abacavir, mitomycin is primarily used in the treatment of various cancers, including gastric, pancreatic, bladder, and breast cancers. Over time, its applications expanded to include intravesical therapy for superficial bladder cancer and use in ophthalmic surgeries, such as glaucoma procedures, to prevent scar formation. Its development and continued use are characterized by its strong cytotoxic activity, which makes it effective but also necessitates careful monitoring due to potential severe adverse effects like bone marrow suppression and organ toxicity.
BRAND NAMES
Mutamycin (widely known injectable form)
Mitozytrex
Mitocin
Mitomycin-C Kyowa (used in some regions, especially Asia)
MECHANISM OF ACTION
Mitomycin acts as a bioreductive alkylating agent that exerts its cytotoxic effects by directly damaging DNA. After enzymatic activation inside the cell (particularly under hypoxic conditions), mitomycin forms highly reactive intermediates that cross-link DNA strands, especially at the N⁶ position of adenine and the O⁶ position of guanine. This cross-linking prevents DNA replication and transcription, ultimately inhibiting cell division and leading to cell death.
PHARMACOKINETICS
Absorption:
Mitomycin is not effectively absorbed orally and is therefore administered intravenously, intravesically (into the bladder), or topically (ophthalmic use). Systemic absorption after intravesical or topical use is minimal but may increase if mucosal integrity is compromised.
Distribution:
Mitomycin is widely distributed throughout body tissues after intravenous administration. It shows moderate plasma protein binding (~10–20%) and penetrates tumor tissues effectively. The volume of distribution is relatively moderate, reflecting distribution beyond plasma into tissues.
Metabolism:
Mitomycin is metabolized primarily in the liver and other tissues through enzymatic reduction to active intermediates. This bioreductive activation is enhanced under hypoxic conditions, which are common in solid tumors.
Elimination:
Elimination occurs mainly via hepatic metabolism, with metabolites excreted through the kidneys. A small fraction of unchanged drug may also be excreted in urine. The plasma half-life is relatively short, but its cytotoxic effects persist due to irreversible DNA binding.
PHARMACODYNAMICS
Mitomycin acts as a DNA cross-linking agent, forming covalent bonds between DNA strands, thereby inhibiting DNA replication, transcription, and protein synthesis. It is cell cycle–nonspecific but particularly effective against rapidly dividing cancer cells. Its preferential activation in hypoxic tumor environments enhances its selectivity for solid tumors.
ADMINISTRATION
Mitomycin is administered via intravenous injection for systemic chemotherapy, intravesical instillation for bladder cancer, and topical application in ophthalmic procedures. Dosing schedules depend on the type of cancer, route of administration, and patient condition, and it must be administered under strict medical supervision.
DOSAGE AND STRENGTH
Mitomycin is available as injectable powder for reconstitution in various strengths (e.g., 2 mg, 5 mg, 10 mg, 20 mg vials). Dosage is individualized based on body surface area (mg/m²), clinical indication, and patient tolerance. Intravesical and ophthalmic doses differ significantly from systemic dosing.
DRUG INTERACTIONS
Mitomycin may increase toxicity when used with other myelosuppressive or cytotoxic agents, leading to enhanced bone marrow suppression. Concurrent use with nephrotoxic drugs may increase the risk of kidney damage.
CONTRAINDICATIONS
Contraindications include severe bone marrow suppression, active infections, hypersensitivity to mitomycin, and caution in patients with impaired renal function.
SIDE EFFECTS
Bone marrow suppression (anemia, leukopenia, thrombocytopenia)
Nausea and vomiting
Fatigue and weakness
Mucositis or stomatitis
Renal toxicity
Pulmonary toxicity (rare but serious)
Local tissue damage if extravasation occurs
OVER DOSAGE
Overdose of Mitomycin is a serious and potentially life-threatening condition due to its potent cytotoxic effects. The most significant manifestation is severe, prolonged bone marrow suppression, leading to leukopenia, thrombocytopenia, and anemia, which increase the risk of infections, bleeding, and fatigue.
TOXICITY
The major toxicity of Mitomycin is dose-dependent bone marrow suppression, which can be delayed and prolonged. Other serious toxicities include renal failure, pulmonary fibrosis, and hemolytic-uremic syndrome (HUS). Due to its potent cytotoxic nature, careful dosing, monitoring of blood counts, and organ function assessment are essential during therapy.
